TP53 and endometrioid adenocarcinoma: Four of these six patients had high-grade serous carcinoma (of which three had a TP53 variant (two stage 3C and one stage 2A) and one had a PIK3CA, KRAS and PTEN variant (high-grade serous carcinoma stage 3C); one had an endometrioid carcinoma stage 2A (and CTNNB1 variant); and one had a clear cell/endometrioid carcinoma stage 1C (and PIK3CA variant)).